• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24069 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Update of commission V18-02]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for stem cell transplantation - Rapid report]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for major liver resection]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for lung cancer - rapid report]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for liver transplantations - rapid report]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for kidney transplantations - Rapid report]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for implantation of unicondylar sled prosthesis - Update of Project V21-02]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantations in adults - Rapid Report]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for heart transplantation]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for complex procedures of the pancreas - Rapid Report]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for complex oesophagael interventions - Rapid report]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome for colorectal cancer surgery – Update of Commission V22-02]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality in revision surgery (knee)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for total knee replacement]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for TAVI]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality for sled prosthesis (knee)]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and quality of treatment outcome in knee replacement revision surgery - Update of Project V21-03]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and outcome in the care of preterm infants and neonates with very low birth weight (VLBW)]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Relationship between use of cannabis and other drugs and psychiatric pathology in adolescents. A proposal of inpatient and outpatient mental health care in the Basque Health Service]
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2025     Austrian Institute for Health Technology Assessment (AIHTA) [Reimbursement models and pricing of digital health technologies and telemonitoring applications – Rapid scoping review]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Reiki therapy in anxiety, depression and pain]
2019     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Rehabilitation for adults with traumatic brain injury]
2010     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rehabilitation after breast cancer, colorectal cancer and prostate cancer – a health technology assessment]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regular exploratory examination of the need for DMP revision - a feasibility study using the example of the DMP "CHD"]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regorafenib: benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regorafenib - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Regorafenib - Addendum to Commission A15-43]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Registries in Austria and their utilisation for healthcare improvement]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Refractive surgery. An HTA report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reduction of salt intake in essential hypertension - Rapid report]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reduction of alcohol consumption in essential hypertension - Rapid report]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Reduction of alcohol consumption in essential hypertension - Rapid report]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) - a health technology assessment]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Reducing mammaplasty for the treatment of patients with breast hypertrophy and chronic dorsalgia]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Reducing bilirubin-induced neurological dysfunction in premature newborns: additional use of bilirubin:albumin ratio in the treatment of hyperbilirubinemia]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Redesigning maternal education: proposal for a framework to draw up an education programme for health and effective birth preparation focused on the needs of women]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Rectal cancer investigation, treatment and follow-up algorithm]
2013     Andalusian Health Technology Assessment Area (AETSA) [Recommendations for the proper use of inverted shoulder prosthesis]
2021     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]
1997     Basque Office for Health Technology Assessment (OSTEBA) [Recommendations for appropriate use of magnetic resonance]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Recombinant follicle-stimulating hormone (rFSH) versus human chorionic gonadotropin (uhMG) for assisted reproductive techniques]
2008     Committee for New Health Technology Assessment (CNHTA) [Recombinant blood coagulation Factor VIII activity test by chromogenic assay]
2016     Gesundheit Osterreich GmbH (GOeG) [Recent evidence on drug therapy of psychological and behavioral symptoms in Alzheimer's dementia]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Recent advances in gene therapy]
2015     Haute Autorite de sante (HAS) [Reassessment of the eligibility criteria of transcather aortic valve implantation by transcutaneous blood or by transapical delivery]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Real-time magnetic resonance imaging (MRI)-guided radiation therapy]
2021     Canary Health Service [Real-time continuous glucose monitoring device for gestational diabetes]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Real time intraoperative magnetic resonance imaging monitoring]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Real time high resolution MR image guidance during irradiation]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Real time continuous glucose monitoring systems]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Reablement for seniors experience a loss of autonomy]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Re-orientation of the Austrian parent-child preventive care programme. Part XII: Economic evaluation of selected screenings during pregnancy]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [RCT of point of care C-reactive protein test and enhanced communication skills for managing acute cough due to lower respiratory tract infection in general practice: cost effectiveness and effect on diagnostic testing, antibiotic prescribing and recovery]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Addendum to Commission A19-59]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (generalized myasthenia gravis) - Benefit assessment according to § 35a SGB V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ravulizumab - Benefit assessment according to §35a Social Code Book V]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Rational use of self-monitoring of blood glucose in type 1 diabetes]
2015     Haute Autorite de sante (HAS) [Rating trabecular bridging micro stents and their act of implanting]
2015     Haute Autorite de sante (HAS) [Rare visceral surgery procedures by laparoscopy]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Rare disease management: experiences from abroad]
2005     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 2]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in children and adolescents with diabetes mellitus type 1 - follow-up commission]
2012     Andalusian Health Technology Assessment Area (AETSA) [Rapid tests for methicillin resistant Staphylococcus aureus. Carrier screening. Executive summary]
2010     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Rapid systematic review on radiotherapy in lung cancer]
2014     Andalusian Health Technology Assessment Area (AETSA) [Rapid review. Gender dysphoria. Diagnosis, treatment and health outcomes]
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid review: alternatives to timolol for the treatment of glaucoma]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: mitigation strategies to counter the shortage of sublingual nitroglycerin sprays and tablets]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: intravesical treatment for bladder cancer]
2017     Andalusian Health Technology Assessment Area (AETSA) [Rapid response: Effectiveness and safety of hyperthermia in combination with radiation therapy and/or chemotherapy in the treatment of breast, cervix and rectum cancer]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: description of specialized geriatric services and their organizational and clinical components in Canada (outside Quebec) and internationally]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Rapid response: Cervical cancer: transition from from Pap test screening to HPV testing]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Rapid on-site evaluations of cytological punctures]
2008     Committee for New Health Technology Assessment (CNHTA) [Rapid isoniazid and rifampicin resistance test(sequencing)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of the artery protection system Embol-X]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximabe in treating B-cell non-hodgkin's lymphoma, low-grade CD 20]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of rituximab for rheumatoid arthritis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of radiofrequency ablation in the surgical treatment of atrial fibrillation]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant melanoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of malignant lymphoma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of head and neck cancers]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of esophageal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of colon and rectal cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Positron Emission Tomography (PET) in the diagnosis, staging and re-staging of breast cancer]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of polyglycolic polymerized matrix artery graft]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of paliperidone for treating schizophrenia]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of natriuretic peptides for diagnosing cardiac insufficiency in patients with acute dyspnea]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of lithium dilution systems for monitoring cardiac output: comparison with available alternatives]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of infliximab for treatment of psoriasis]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of everolimus to prevent renal transplant rejection]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for metastatic breast cancer]
2008     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of capecitabine for Dukes'C colorectal cancer (stage III)]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Bortezomib in treating refractory multiple myeloma]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of basal action recombinant insulin, analogous to human insulin, (glargine and determir) for treating type 1 diabetes mellitus]
2009     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Rapid HTA on the use of Alteplase (rt-PA) in the cerebral vascular ischemic accident]